About Surface Oncology®

We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.

Surface Oncology is driven to deliver transformational outcomes for people with cancer who have no effective treatment options. We push ourselves to break through across all dimensions of our work by:

Our leaders and advisors drive the bold pursuit of transformative cancer care.

To break through the current boundaries of medical science, collaborations are a crucial part of our strategy. Surface has entered into two strategic collaborations to advance our next-generation cancer therapies.

In January 2016, Surface entered into an agreement with Novartis to exclusively license worldwide rights to NZV930 (formerly SRF373), Surface’s fully human CD73 antibody. Surface received an upfront payment of $70 million from Novartis and is entitled to potential milestone payments upon the achievement of specified development and sales milestones of $525 million, as well as tiered royalties.

In December 2020, Surface entered into an agreement with GSK to exclusively license worldwide rights to SRF813, Surface’s fully human CD112R antibody.  Surface received an upfront payment of $85 million from GSK and is entitled to an additional $730 million in future milestone payments, as well as tiered royalties on global net sales.

Are you interested in partnering with Surface? Please contact us at partner@surfaceoncology.com.